<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365675">
  <stage>Registered</stage>
  <submitdate>21/01/2014</submitdate>
  <approvaldate>30/01/2014</approvaldate>
  <actrnumber>ACTRN12614000117617</actrnumber>
  <trial_identification>
    <studytitle>Carbetocin  versus syntometrine for prevention of postpartum hemorrhage after cesarean section</studytitle>
    <scientifictitle>Carbetocin  versus syntometrine for prevention of postpartum hemorrhage after cesarean section</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>postpartum hemorrhage</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>single 100 microgram IV dose of carbetocin (Pabal)  after fetal extraction and before placental removal</interventions>
    <comparator>single dose IV combination of 5 IU oxytocin and 0.2 mg ergometrine  after fetal extraction and before placental removal</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>occurrence of postpartum hemorrhage (defined as a blood loss of greater than 1000 ml of blood following caesarean section)</outcome>
      <timepoint>24 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>need of additional oxytocic</outcome>
      <timepoint>24 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>side effects of drugs e.g. nausea, vomiting,metallic taste, shivering, flushing, headache, dizziness, dyspnea, and itching assessed by number of participants experienced that. </outcome>
      <timepoint>24 hours
</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>37  40 weeks of gestational age
noncomplicated pregnancy. 
Cesarean sections are a mixture of planned and emergency interventions under regional anaesthesia </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>placenta previa
coagulopathy
preeclamptic 
known sensitivity to oxytocin or methergine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>Simple randomisation using a randomisation table from a statistic book</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate>1/06/2011</actualstartdate>
    <anticipatedenddate>30/05/2013</anticipatedenddate>
    <actualenddate>30/05/2013</actualenddate>
    <samplesize>450</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Ahmed Maged</primarysponsorname>
    <primarysponsoraddress>Kasr Aini medical school . 135 king Faisal street, Haram Giza Egypt. postal code 12151</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Ahmed Maged</fundingname>
      <fundingaddress>135 king Faisal street, Haram Giza Egypt. postal code 12151</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Ali abdelhafiz 
</sponsorname>
      <sponsoraddress>Kasr Aini medical school .1 Kasr Aini street Manial Cairo Egypt Postal code 12245</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A double blind randomized study conducted on 450 pregnant subjected randomly either to  single 100 microgram IV dose of carbetocin (150 women) or combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of Postpartum hemorrhage after Cesarean section</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Kasr Aini local ethical committe</ethicname>
      <ethicaddress>1 Kasr Aini street Manial Cairo Egypt Postal code 12245</ethicaddress>
      <ethicapprovaldate>20/04/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Ahmed Maged</name>
      <address>Kasr Aini medical school. 135 King faisal street , Haram , Giza Egypt. Postal code 12151</address>
      <phone>+2001005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ahmed Maged</name>
      <address>Kasr Aini medical school.135 King faisal street , Haram , Giza Egypt. Postal code 12151</address>
      <phone>+2001005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ahmed Maged</name>
      <address>Kasr Aini medical school. 135 King faisal street , Haram , Giza Egypt. Postal code 12151</address>
      <phone>+2001005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ahmed Maged</name>
      <address>135 King faisal street , Haram , Giza Egypt. Postal code 12151</address>
      <phone>+2001005227404</phone>
      <fax />
      <email>prof.ahmedmaged@gmail.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>